Citation Impact
Citing Papers
Global Cancer Incidence and Mortality Rates and Trends—An Update
2015 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus
2014 StandoutNobel
Stem Cell–Derived Culture Models of Hepatitis E Virus Infection
2018 StandoutNobel
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Pan-Genotype Hepatitis E Virus Replication in Stem Cell–Derived Hepatocellular Systems
2017 StandoutNobel
Regulation of microRNA function in animals
2018 Standout
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection
2018
Hepatocellular carcinoma
2018 Standout
The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus–induced microRNAs
2013
Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies
2016 StandoutNobel
Burden of liver diseases in the world
2018 Standout
Regulation of hepatic innate immunity by hepatitis C virus
2013
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection
2017
Modelling hepatitis C therapy—predicting effects of treatment
2015
Designing an HCV vaccine: a unique convergence of prevention and therapy?
2017
Hepatitis C
2015
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
2017
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Nonalcoholic fatty liver disease in Asia: emerging perspectives
2016
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Hepatitis E virus persists in the presence of a type III interferon response
2017
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents
2016
HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies
2011
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores
2019
Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis
2015
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
2018
Direct-acting antiviral agents for HCV infection affecting people who inject drugs
2017
Interferon Lambda Alleles Predict Innate Antiviral Immune Responses and Hepatitis C Virus Permissiveness
2014 StandoutNobel
Hepatitis C virus infection
2017
Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection
2010
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients
2015
Global burden of liver disease: 2023 update
2023 Standout
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
2015
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
2020 Nature
Hepatitis C Virus: 30 Years after Its Discovery
2019 StandoutNobel
IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza
2014 StandoutNobel
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Taming a beast: lessons from the domestication of hepatitis C virus
2019 StandoutNobel
Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus
2019 StandoutNobel
Innate Immune Responses to Hepatitis C Virus
2013 StandoutNobel
Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C
2013
Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990–2019
2021
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
2016
Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent From Interferons
2017 StandoutNobel
SARS-CoV-2 vaccines in development
2020 StandoutNature
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Genetic Variation at IFNL4 Influences Extrahepatic Interferon-Stimulated Gene Expression in Chronic HCV Patients
2017 StandoutNobel
Polymorphisms in melanoma differentiation‐associated gene 5 link protein function to clearance of hepatitis C virus
2014 StandoutNobel
Sexually Transmitted Infections Treatment Guidelines, 2021
2021 Standout
Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM
2018
The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections
2014 StandoutNobel
ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication
2017
Hepatitis C Virus
2016
Characterization of nonprimate hepacivirus and construction of a functional molecular clone
2015 StandoutNobel
Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus
2019 StandoutNobel
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
2017
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1
2019 StandoutNobel
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Viral persistence, liver disease, and host response in a hepatitis C–like virus rat model
2017 StandoutNobel
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Perspectives on HCV: Current Therapeutic Regimens and Drug–Drug Interactions
2017
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
2016 StandoutNobel
Guidelines for the management of hemophilia
2012 Standout
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Works of Anu Osinusi being referenced
Rapid Development of Advanced Liver Fibrosis after Acquisition of Hepatitis C Infection during Primary HIV Infection
2009
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1–infected patients
2014
High interferon‐stimulated gene ISG‐15 expression affects HCV treatment outcome in patients co‐infected with HIV and HCV
2013
HIV/Hepatitis C Virus−Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders Do
2010
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B -unfavorable genotype patients: Impaired viral kinetics and therapeutic response
2012
Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy
2015
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials
2016
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
2015
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
2014
290 - Long-Term Follow-Up of Patients with Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens
2018
Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen
2017
Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse
2014
Direct‐acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study
2018
Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study
2016
Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies
2016
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study
2017
O14 USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 IN PATIENTS COINFECTED WITH HIV
2014
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
2020